AMWatch

Novo Ventures investerer trecifret millionbeløb i schweizisk kræftselskab

Et schweizisk biotekselskab, som udvikler antistofkonjugater mod kræft, har udvidet en tidligere serie B-finansieringsrunde med en ny trecifret millioninvestering fra Novo Ventures.

Photo: Novo Holdings/PR

Det danske investeringsselskab Novo Holdings har torsdag sendt et trecifret millionbeløb i armene på det schweiziske biotekselskab NBE Therapeutics. Det skriver parterne i en pressemeddelelse.

Helt konkret har Novo Holdings investeret 20 mio. schweiziske franc – eller 129 mio. kr. – i biotekselskabet, som man nu er blevet storaktionær i. Det sker gennem afdelingen Novo Ventures, og Nanna Lüneborg, der er partner i den afdeling, træder samtidig ind i bestyrelsen i NBE Therapeutics.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Savills IM working hard on first Nordic residential investment

The global property investor has plans to expand its growing portfolio in Denmark with a new asset class, residential real estate, "very soon," says Head of Nordics Peter Broström. The manager still believes in the office and retail sectors, despite the pandemic and rising inflation.

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch